KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorErgun, Yakup
dc.contributor.authorAcikgoz, Yusuf
dc.contributor.authorBal, Oznur
dc.contributor.authorUcar, Gokhan
dc.contributor.authorDirikoc, Merve
dc.contributor.authorYildirim, Eda Caliskan
dc.contributor.authorAkdeniz, Nadiye
dc.date.accessioned2024-04-24T17:07:47Z
dc.date.available2024-04-24T17:07:47Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: In this study, we aimed to investigate the frequency, prognostic effect of codon, and amino acid-specific KRAS mutations in patients with metastatic colorectal cancer (mCRC) and their predictive effect on irinotecan and oxaliplatin during first-line treatment. Methods: The data of 304 mCRC patients were retrospectively evaluated between 2010 and 2018. Patients were categorized according to the most prominent codon and amino acid mutation and their prognostic features were analyzed. Results: In total, 274 patients were included in the study and 128 patients (47%) revealed KRAS mutation. Median follow-up time was 19.8 months (range; 1.6-96). The median overall survival rates for patients with codons 12 and 13 mutations were 25.4 and 22.2 months, respectively (p = 0.4). Moreover, the median overall survival for the codon 12 mutant patients who received irinotecan-based chemotherapy in the first-line treatment was 42.7 months, whereas for the codon 13 mutant and KRAS wild-type patients, it was 18.3 and 23.9 months, respectively (codon 12 vs. codon 13; HR: 0.31, p = 0.03, codon 12 vs. wild-type; HR: 0.45, p = 0.03). Conclusion: The significant survival advantage was observed in patients with codon 12 mutations who received irinotecan-based chemotherapy as a first-line treatment.en_US
dc.identifier.doi10.1080/14737159.2019.1693266
dc.identifier.endpage1140en_US
dc.identifier.issn1473-7159
dc.identifier.issn1744-8352
dc.identifier.issue12en_US
dc.identifier.pmid31718325
dc.identifier.scopus2-s2.0-85075201999
dc.identifier.scopusqualityQ1
dc.identifier.startpage1131en_US
dc.identifier.urihttps://doi.org/10.1080/14737159.2019.1693266
dc.identifier.urihttps://hdl.handle.net/11468/16987
dc.identifier.volume19en_US
dc.identifier.wosWOS:000497229500001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Asen_US
dc.relation.ispartofExpert Review of Molecular Diagnostics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Canceren_US
dc.subjectPredictiveen_US
dc.subjectIrinotecanen_US
dc.subjectKrasen_US
dc.subjectCodon 12en_US
dc.titleKRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal canceren_US
dc.titleKRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu